Ticagrelor Patent Expiration
Ticagrelor is used for reducing the rate of cardiovascular events, including myocardial infarction and stroke, in patients with coronary artery disease or who had acute coronary syndrome. It was first introduced by Astrazeneca Pharmaceuticals Lp
Ticagrelor Patents
Given below is the list of patents protecting Ticagrelor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brilinta |
US10300065 (Pediatric) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | Jul 27, 2036 | Astrazeneca |
| Brilinta | US10300065 | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | Jan 27, 2036 | Astrazeneca |
| Brilinta |
US8425934 (Pediatric) | Pharmaceutical compositions | Oct 17, 2030 | Astrazeneca |
| Brilinta | US8425934 | Pharmaceutical compositions | Apr 17, 2030 | Astrazeneca |
| Brilinta |
USRE46276 (Pediatric) | Triazolo(4,5-D)pyrimidine compounds |
Apr 30, 2025
(Expired) | Astrazeneca |
| Brilinta | USRE46276 | Triazolo(4,5-D)pyrimidine compounds |
Oct 30, 2024
(Expired) | Astrazeneca |
| Brilinta | US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul 09, 2021
(Expired) | Astrazeneca |
| Brilinta | US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul 09, 2021
(Expired) | Astrazeneca |
| Brilinta | US6525060 | Triazolo(4,5-d)pyrimidine compounds |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US6525060 | Triazolo(4,5-d)pyrimidine compounds |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul 15, 2018
(Expired) | Astrazeneca |
| Brilinta | US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul 15, 2018
(Expired) | Astrazeneca |
Ticagrelor's Family Patents
Explore Our Curated Drug Screens
Ticagrelor Generic API Manufacturers
Several generic applications have been filed for Ticagrelor. The first generic version for Ticagrelor was by Watson Laboratories Inc and was approved on Sep 4, 2018. And the latest generic version is by Dr Reddys Laboratories Ltd and was approved on Oct 29, 2024.
Given below is the list of companies who have filed for Ticagrelor generic, along with the locations of their manufacturing plants worldwide.
1. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Apr 21, 2023 |
2. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Discontinued | ORAL | N/A | Jan 23, 2019 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Oct 29, 2024 |
4. HISUN PHARM HANGZHOU
Hisun Pharmaceutical Hangzhou Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Hisun Pharm Hangzhou.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Jan 23, 2019 |
5. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Apr 7, 2020 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||
6. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Discontinued | ORAL | N/A | Jul 9, 2021 |
| 90MG | tablet | Discontinued | ORAL | N/A | Jul 9, 2021 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
7. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Aug 16, 2024 |
8. SUNSHINE
Sunshine Lake Pharma Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Sunshine.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Apr 6, 2020 |
Manufacturing Plant Locations New
Sunshine's manufacturing plants are situated in 6 countries - United States, Peru, India, Thailand, China, Mozambique. Given below are the details of these plant locations as well as the firm names of Sunshine as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||||||||||||||
| Peru |
| |||||||||||||||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||||||||||||||
| Thailand |
| |||||||||||||||||||||||||||||||||||||||||
| China |
| |||||||||||||||||||||||||||||||||||||||||
| Mozambique |
| |||||||||||||||||||||||||||||||||||||||||
9. WATSON LABS INC
Watson Laboratories Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Sep 4, 2018 |
| 90MG | tablet | Prescription | ORAL | AB | Sep 4, 2018 |